Abstral REMS Assessment To Look At Impact On Patient Access, Health Care System

The extensive REMS assessment for ProStrakan's Abstral details the data collection burden sponsors face as they institute restricted distribution programs and FDA asks more questions about the burden placed on the health care system as well as the effects on patient access to medications.